
AstroRx® for ALS
AstroRx® is an advanced cell therapy product (human healthy Astrocytes, supporting cells for neurons/CNS) designed to slow the progression of ALS by multiple mechanisms of action of nurturing and protecting the neurons in the CNS.
Following sucessful Phase 1/2a study in 10 ALS patients, the company was granted IND approval to conduct a Phase IIa multi-site clinical trial in the US by the FDA. In addition to ALS, AstroRx® cell product can be beneficial in other neurodegenerative diseases indications, such as Glaucoma and MS, established in POC studies in animal models.

NewcelX Earns FDA Approval of its IND Application For its US Multi-Site Phase IIa Clinical Trial of AstroRx® to Treat ALS AstroRx® - Functional Healthy Astrocytes to Protect ALS-Diseased Motor Neurons.
ALS is a rapidly progressive and fatal neurological disease, causing death on average within 3-5 years from time of diagnosis. The disease attacks motor neurons responsible for controlling muscles and leads to paralysis and impaired breathing and swallowing. Multiple studies have demonstrated that astrocytes play a crucial role in ALS disease progression. In ALS patients, the astrocytes malfunction and attack the neurons.
NewcelX’s innovative approach is to use fully differentiated astrocytes as a regenerative medicine therapy for ALS – AstroRx® to slow the progression of the disease and improve the patient's life quality and life expectancy. AstroRx® is administered directly into the patient’s spinal cord fluid by a standard intrathecal injection under local anesthesia. Pre-clinical studies in ALS animal models showed that AstroRx® is a safe treatment that provides systemic support to damaged motor neurons, increasing the life expectancy and motor functions.

NewcelX has received FDA clearance to commence a phase IIa clinical trial in the US according to the Investigational New Drug (IND) application that was submitted in February 2023. The trial will test its lead neurological cell therapy product AstroRx® in repeated dosing of three-month intervals for the treatment of patients with ALS.
The planned clinical trial follows a first in human phase I/IIa clinical trial previously conducted by the company in Israel, in which AstroRx® was injected into the spinal cord fluid using a standard lumbar puncture procedure. In this phase I/IIa clinical trial NewcelX demonstrated a good safety profile and clinically meaningful decline in the disease progression during the first 3-months follow-up period.